Development Considerations of Antimicrobial Drugs for the Treatment of Uncomplicated Urinary Tract Infections (uUTI)—June 3, 2022

Speakers and Panelists: Affiliations and Disclosures

Iain J. Abbott, MBBS, PhD
Infectious Diseases Specialist Physician & Clinical Microbiologist
Department of Infectious Diseases & Microbiology Unit, Alfred Hospital and Central Clinical School, Monash University
Melbourne, Victoria, Australia

Tomefa E. Asempa, PharmD
Associate Director, Clinical and Translational Infectious Diseases Research Center for Anti-Infective Research and Development
Hartford Hospital
Hartford, CT

Timothy Bensman, PharmD, PhD
Clinical Pharmacology Reviewer
Division of Infectious Disease Pharmacology (DIDP), Office of Clinical Pharmacology (OCP)
Office of Translational Sciences (OTS), CDER, FDA
Silver Spring, MD

Radu Botgros, MD
Scientific Officer
Biological Health Threats and Vaccines Strategy
Clinical Studies and Manufacturing Task Force
European Medicines Agency (EMA)
Amsterdam, The Netherlands

Erica Brittain, PhD
Mathematical Statistician and Deputy Branch Chief
Biostatistics Research Branch
National Institute of Allergy and Infectious Diseases (NIAID), NIH
Bethesda, Maryland

Zhixia (Grace) Yan Danielsen, PhD
Deputy Division Director
DIDP, OCP
OTS, CDER, FDA
Silver Spring, MD
Dimitri Drekonja, MD, MS  
Associate Professor of Medicine, University of Minnesota  
Chief, Infectious Disease Section, Minneapolis VA Health Care System  
Minneapolis, MN

Scott Evans, PhD, MS  
Director, The Biostatistics Center  
Professor and Founding Chair, Department of Biostatistics and Bioinformatics  
Milken Institute School of Public Health  
George Washington University  
Washington, DC

Kerian Grande Roche, PhD  
Reviewer, Clinical Microbiology  
Division of Anti-infectives (DAI), Office of Infectious Diseases (OID)  
Office of New Drugs (OND), CDER, FDA  
Silver Spring, MD

Kalpana Gupta, MD, MPH  
Professor of Medicine/Infectious Diseases, Boston University School of Medicine  
Associate Chief of Staff and Chief of Infectious Diseases, VA Boston HealthCare System  
Lecturer in Medicine, Harvard Medical School  
Boston, MA

Tom Hadley  
President and CCO  
UTILITY therapeutics  
Altrincham, Cheshire  
United Kingdom WA14 2DT

Hiwot Hiruy, MD, PhD  
Lead Physician  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

Thomas Hooton, MD  
Professor, Clinical Medicine  
Miller School of Medicine  
University of Miami  
Miami, FL
Dmitri Iarikov, MD, PhD  
Deputy Division Director  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

Salim Janmohamed, BSc, MBBS  
Senior Clinical Director,  
Development Clinical Sciences, R&D, GlaxoSmithKline  
980 Great West Road  
Brentford  
Middlesex TW8 9GS  
United Kingdom

Nadia Kadry, PhD  
Postdoctoral Fellow  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

Peter Kim, MD, MS  
Division Director  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

Xianbin Li, PhD  
Reviewer, Biostatistics  
Division IV, Office of Biostatistics  
OTS, CDER, FDA  
Silver Spring, MD

Cristina Miglis, PharmD, MS, BCPS  
Reviewer, Clinical Pharmacology  
Division of Infectious Disease Pharmacology (DIDP), Office of Clinical Pharmacology (OCP)  
OTS, CDER, FDA  
Silver Spring, MD

Harry L.T. Mobley, PhD  
Frederick G. Novy Distinguished University Professor  
Department of Microbiology and Immunology  
University of Michigan Medical School  
Ann Arbor, MI
Mukil Natarajan, MD
Clinical Reviewer
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Valerie Price
Patient Representative
Quebec City, Canada

Sailaja Puttagunta, MD
Chief Medical Officer
Iterum Therapeutics
Old Saybrook, CT

Jason A. Roberts PhD, B Pharm (Hons), B App Sc, FSHP, FISAC
Acting Director
University of Queensland Centre for Clinical Research, The University of Queensland,
Royal Brisbane and Women’s Hospital, Butterfield St
Brisbane, Queensland

Keith A. Rodvold, Pharm.D., FCCP, FIDSA
UIC Distinguished Professor
Co-Director, Section of Infectious Diseases Pharmacotherapy
Colleges of Pharmacy and Medicine
University of Illinois Chicago (UIC)
Chicago, IL

Dan Rubin, PhD
Statistical Team Leader
Division of Biometrics IV, Office of Biostatistics
OTS, CDER, FDA
Silver Spring, MD

Nicole Scangarella-Oman, MS
Scientific Director
Clinical Microbiology
Infectious Diseases Research Unit (IDRU)
GlaxoSmithKline Collegeville, PA

Jalal Sheikh, PhD
Clinical Microbiology Reviewer
DAI, OID
OND, CDER, FDA
Silver Spring, MD
Ann Stapleton, MD, FACP, FIDSA  
Professor Emeritus of Medicine, University of Washington  
Program Director, Infectious Disease Fellowship and Attending Physician  
Eisenhower Health  
Rancho Mirage, CA

Barbara Trautner, MD, PhD  
Professor, Infectious Diseases, Department of Medicine, Baylor College of Medicine  
Deputy Associate Chief of Staff for Clinical Research, Michael E. DeBakey VA Medical Center  
Director, Network of Dedicated Enrollment Sites (NODES), Michael E. DeBakey VA Medical Center  
Houston TX

Janice Tufte  
Patient Representative  
Seattle, WA

Voluntary Disclosures


Tomefa Asempa: received research grants from the FDA (CDER/OID), Spero Therapeutics, and Venatorx.

Scott Evans: receives grant support from the National Institutes of Health (NIH) and Aceragen. He receives royalties from Taylor and Francis and funding for editorial activities from DeGruyter. He has been a Board member for the American Statistical Association, the Society for Clinical Trials, and Frontier Science Foundation. He has received travel support or honorariums from the NIH; FDA; Council for International Organizations of Medical Sciences (CIOMS), the American Statistical Association; Osaka University; National Cerebral and Cardiovascular Center of Japan; Society for Clinical Trials; the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION); the Deming Conference on Applied Statistics; the International Chinese Statistical Association; and the Clinical Trials Transformation Initiative (CTTI). He has been a consultant to the Breast International Group (BIG), Janssen, Takeda, Pfizer, Roche, Novartis, Genentech, AstraZeneca, Teva, Vir, Tracon, Candel, Microbition, Endologix, Chemocentryx, Becton Dickenson, Atricure, International Drug Development Institute, Akouos, Apellis, DayOneBio, Alexion, Roivant, Neovasc, Nobel Pharma, Horizon, Rakuten, Duke University, University of Pennsylvania, Nuvelution, Abbvie, Clover, FHI Clinical, Lung Biotech, and SAB Biopharm.
Kalpna Gupta: receives research support on the topic of UTI from VA Health Services Research and Development. She has served as a consultant for Qiagen, Utility Therapeutics, Nabriva Therapeutics, GlaxoSmithKline, Rebiotix, Spero Therapeutics, First Light Diagnostics, Shionogi, Iterum Therapeutics, Paratek Pharmaceuticals. She receives royalties from UpToDate. She receives honoraria and consulting fees from Pri-Med Institute for development and delivery of Continuing Medical Education material. She receives honoraria (deferred) from Harrison’s Textbook of Internal Medicine. She is the Chair of the current Infectious Diseases Guideline for Treatment of UTI and a member of the IDSA UTI Guideline update committee.

Salim Janmohamed: Full time employee of GlaxoSmithKline

Harry Mobley: has served as consultant for GlaxoSmithKline

Sailaja Puttagunta: is an employee and shareholder of Iterum Therapeutics

Jason Roberts: Consultancies/Advisory Boards – Wolters Kluwer (2022); Gilead (2021); Summit (2021); Pfizer (2020); Sandoz (2020); MSD (2019)

Speaking Fees – MSD (2022); Pfizer (2021), Cipla (2021)


Keith Rodvold: received consulting fees from Janssen Pharmaceutica N.V. as a member of a data safety monitoring board. He has received consulting fees from Brii Bioscience, Clinartis LLC (for research studies with Sinovent, Sero Therapeutics, and Venatorx Pharmaceuticals), Shionogi Inc., Spero Therapeutics, Qpex/The Medicines Company, and Utility Therapeutics.

Nicole Scangarella-Oman: full time employee and shareholder of GlaxoSmithKline.

Barbara Trautner: is a full-time employee of Michael E. DeBakey VA Medical Center and has received research funding for a clinical trial from Genentech. Dr. Trautner also served as a one-time consultant for Genentech.